lncRNA MNX1-AS1在非小细胞肺癌中的表达及调控PI3K/AKT通路对癌细胞生物学行为的影响

doi:10.3969/j.issn.1006-6233.2023.01.003

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (2297 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the biological function and possible mechanism of long non-coding RNA (lncRNA) MNX1-AS1 (lncRNA MNX1-AS1) in non-small cell lung cancer (NSCLC). Methods: The cancer tissue and adjacent tissue samples of 75 NSCLC patients who underwent surgical treatment in our hospital from June 2017 to March 2019 were taken. RT-qPCR method was performed to detect the expression level of lncRNA MNX1-AS1 in the samples, the correlation between the expression of lncRNA MNX1-AS1 and the clinicopathological characteristics and prognosis of NSCLC was analyzed; the NSCLC cell line PC-9 cells were cultured in vitro and transfected with si-MNX1-AS1 (si-MNX1-AS1 group) and si-NC (si-NC group), respectively. the proliferation of PC-9 cells in each group was detected by MTT assay and EdU assay; Transwell chamber assay was performed to detect cell migration and invasion; Western blot assay was performed to detect the expression of PI3K/AKT pathway-related proteins. Results: The expression level of lncRNA MNX1-AS1 was obviously higher in NSCLC cancer tissues and cell lines (P<0.05). The expression of lncRNA MNX1-AS1 was associated with TNM stage and lymphatic metastasis (P<0.05), Kaplan-Meier survival analysis showed that the 3-year cumulative survival rate of patients in the high expression group of lncRNA MNX1-AS1 was obviously lower than that in the low expression group (42.11% vs 81.08%, χ²=11.132, P=0.001); compared with the si-NC group, the proliferation, migration and invasion abilities of PC-9 cells in the si-MNX1-AS1 group and the protein expression levels of p-PI3K, p-AKT and p-mTOR were obviously decreased (P<0.05). Conclusion: The expression level of lncRNA MNX1-AS1 is increased in NSCLC, which may affect the proliferation, migration and invasion of NSCLC cells by activating the PI3K/AKT pathway, and promote the occurrence and development of NSCLC.

Key words： Non-small cell lung cancer Long non-coding RNA MNX1-AS1 PI3K/AKT pathway Migration Invasion

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Guixia
	DENG Kelan
	LI Yinping

Cite this article:

LIU Guixia,DENG Kelan,LI Yinping. Expression of lncRNA MNX1-AS1 in Non-Small Cell Lung Cancer and the Effect of Regulation of PI3K/AKT Pathway on the Biological Behavior of Cancer Cells[J]. HeBei Med, 2023, 29(1): 13-18.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.01.003 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I1/13

[1] Imyanitov EN,Iyevleva AG,Levchenko EV.Molecular testing and targeted therapy for non-small cell lung cancer:current status and perspectives[J].Crit Rev Oncol Hematol,2021,157(1):1-33.
[2] Reggiardo RE,Maroli SV,Kim DH.LncRNA biomarkers of inflammation and cancer[J].Adv Exp Med Biol,2022,1363(1):121-145.
[3] Shen Y,Lv M,Fang Y,et al.LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis[J].Ovarian Res,2021,14(1):161-175.
[4] 刘高峰,张勇,张小贞,等.LncRNA MNX-AS1在非小细胞肺癌组织中的表达及临床意义[J].河北医学,2021,27(3):486-490.
[5] Choi S,Park J.Surgical outcomes and prognosis of non-small-cell lung cancer in patients with chronic lung diseases:a retrospective analysis[J].Eur Cardiothorac Surg,2020,58(2):357-364.
[6] 饶德新,潘丽红,刘恒,等.血清LncRNA ANCR、LncRNA LINC00355与非小细胞肺癌临床病理特征及预后的关系[J].实用癌症杂志,2022,37(4):556-559,582.
[7] Wu QN,Luo XJ,Liu J,et al.MYC-activated LncRNA MNX1-AS1 promotes the progression of colorectal cancer by stabilizing YB1[J].Cancer Res,2021,81(10):2636-2650.
[8] 张晓丹,徐毅,杜德奇,等.干扰长链非编码RNA MNX1-AS1对卵巢癌细胞的干样特性、氧化应激以及线粒体功能损伤的影响[J].解剖学杂志,2021,44(5):394-398.
[9] Liu G,Guo X,Zhang Y,et al.Expression and significance of LncRNA MNX1-AS1 in non-small cell lung cancer[J].Onco Targets Ther,2019,12(1):3129-3138.
[10] Wang J,Xing H,Nikzad AA,et al.Long noncoding RNA MNX1 antisense RNA 1 exerts oncogenic functions in bladder cancer by regulating miR-218-5p/RAB1A axis[J].Pharmacol Exp Ther,2020,372(3):237-247.
[11] Liu H,Han L,Liu Z,et al.Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway[J].Cell Physiol,2019,234(8):13843-13850.
[12] Yan S,Zhang B,Feng J,et al.FGFC1 selectively inhibits erlotinib-resistant non-small cell lung cancer via elevation of ROS mediated by the EGFR/PI3K/Akt/mTOR pathway[J].Front Pharmacol,2022,12(1):1-21.
[13] 王天雨,唐旭东.PI3K/Akt/mTOR信号通路相关lncRNA在非小细胞肺癌发展中的最新进展[J].医学综述,2022,28(4):692-699.
[14] Li F,Gu F,Li Q,et al.ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway[J].Biochem Mol Toxicol,2021,35(5):1-12.
[15] Cheng Y,Pan Y,Pan Y,et al.MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer[J].Cancer Manag Res,2019,11(1):803-812.